CTOs on the Move

RxWiki

www.rxwiki.com

 
RxWiki Inc. is a rapidly growing Digital Health company connecting pharmacies and patients through its Digital Pharmacist (www.digitalpharmacist.com) SaaS platform and original Pharmacist written and verified content. RxWiki`s Digital Pharmacist platform powers the websites and mobile applications of 1,300 specialty and community pharmacy brands. Patients can manage their medications, complete digital refills and engage with medication adherence programs. RxWiki`s original Pharmacist written and verified content includes 20,000 original health articles, 7,500 health-related videos, and 100 disease condition channels. More than 3,700 community pharmacies and national health brands, like Health Mart and Health Media Network, license this content to engage ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rxwiki.com
  • 4315 Guadalupe St. Suite 200
    Austin, TX USA 78751
  • Phone: 877.959.7550

Executives

Name Title Contact Details

Similar Companies

BLOSSOM SOUTH

BLOSSOM SOUTH is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TB12

TB12 is transforming health by empowering athletes everywhere to improve longevity, prevent injury, and do what they love better and for longer. Our holistic approach to health & wellness includes adequate hydration, mainly plant-based nutrition, funct...

South End Community Health Center

South End Community Health Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Boston, MA. To find more information about South End Community Health Center, please visit www.sechc.org

Trust RCM

Trust RCM is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.